Glenmark opens $100M plant in North Carolina, its first in U.S.

Glenmark's $100 million plant in Monroe, North Carolina. (North Carolina Biotechnology Center)

Glenmark was among a wave of drugmakers that decided having U.S. manufacturing was a good hedge when FDA crackdowns on facilities in India were keeping some of them from exporting to the U.S. The Mumbai-based Glenmark will see if that bet pays off when a $100 million plants open in North Carolina on Tuesday.

The 100,000-square-foot facility is designed to produce not only a variety of fixed dose formulations in tablets and capsules but also vials and prefilled syringes as well as ampoules for inhaled formulations, the drugmaker said. The company expects to build employment there well beyond the 168 workers currently on site.